Joaquin Duato will be leading Johnson & Johnson as a new CEO of Johnson & Johnson (JNJ) - Get Johnson & Johnson (JNJ) Report starting January 3. Duato, 59, has been working for the company for over 30 years.
“I am honored to serve as Johnson & Johnson’s next CEO,” said Duato, in a statement, on Thursday. “Our Company has an unmatched healthcare platform: we are a global pharmaceutical leader with a robust pipeline of transformational and innovative medicines, our Medical Device business is at the forefront of applying cutting-edge technology to deliver physician and patient-centric products and solutions and our Consumer Health business continues to evolve its portfolio of iconic heritage brands and innovative growth brands."
A dual citizen of Spain & America, Duato also served as the chairman of PhRMA, a group representing America’s leading biopharmaceutical research companies, in 2017. Also, in the same year, Healthcare Businesswomen’s Association named him an Honorable Mentor.
The company's outgoing CEO Alex Gorsky says he has the utmost confidence in Joaquin to lead the company.
“Over our more than 25 years of working together, he has always demonstrated a passion for solving complex medical and business challenges," said Gorsky. "I look forward to working closely with Joaquin in my role as Executive Chairman to help write Johnson & Johnson’s next chapter.”
Duato became the Vice Chairman of the Executive Committee at the company in July 2018.
Duato holds an MBA from ESADE in Spain, and a Master of International Management from Thunderbird in Arizona.